Alfonso Quintás-cardama, MD | Authors

Management of Patients With Resistant or Refractory Chronic Myelogenous Leukemia

April 15, 2008

The introduction of imatinib mesylate (Gleevec) has dramatically changed the management and prognostic outlook of patients with chronic myeloid leukemia (CML).